ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing

Contributed by: GlobeNewswire

Tags

obesity

More Like This

PR Newswire associated0

Gan & Lee Pharmaceuticals' Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical Studies

PR Newswire associated0

Gan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial

MHRA approves GLP –1 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults

GlobeNewswire associated0

Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study

PR Newswire associated0

Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)

61st ERA Congress: Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals

UEG Week: Novel procedure combined with semaglutide may eliminate insulin dependency in type 2 diabetes

PR Newswire associated0

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)